Akebia Therapeutics, Inc. (AKBA) DCF Valuation

Akebia Therapeutics, Inc. (AKBA) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Akebia Therapeutics, Inc. (AKBA) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Akebia Therapeutics, Inc. (AKBA) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Simplifique la valoración de Akebia Therapeutics, Inc. (AKBA) con esta calculadora DCF personalizable! Con las finanzas reales de Akebia y las entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Akebia en minutos.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 335.0 295.3 213.6 292.6 194.6 177.1 161.2 146.6 133.4 121.4
Revenue Growth, % 0 -11.85 -27.68 37 -33.49 -9 -9 -9 -9 -9
EBITDA -247.6 -341.0 -226.0 -43.3 -6.9 -103.5 -94.2 -85.7 -78.0 -71.0
EBITDA, % -73.92 -115.47 -105.8 -14.78 -3.53 -58.45 -58.45 -58.45 -58.45 -58.45
Depreciation 36.4 33.6 36.1 35.3 37.6 25.0 22.7 20.7 18.8 17.1
Depreciation, % 10.87 11.37 16.92 12.06 19.33 14.11 14.11 14.11 14.11 14.11
EBIT -284.1 -374.6 -262.1 -78.5 -44.5 -118.5 -107.8 -98.1 -89.3 -81.2
EBIT, % -84.79 -126.85 -122.71 -26.84 -22.86 -66.9 -66.9 -66.9 -66.9 -66.9
Total Cash 147.7 268.7 149.8 90.5 42.9 91.5 83.2 75.7 68.9 62.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 38.9 26.9 51.6 41.1 39.3
Account Receivables, % 11.6 9.09 24.15 14.03 20.19
Inventories 116.3 61.0 38.2 21.8 15.7 31.4 28.6 26.0 23.7 21.6
Inventories, % 34.73 20.66 17.88 7.44 8.06 17.76 17.76 17.76 17.76 17.76
Accounts Payable 39.2 41.3 33.6 18.0 14.6 19.5 17.8 16.2 14.7 13.4
Accounts Payable, % 11.71 13.99 15.73 6.16 7.52 11.02 11.02 11.02 11.02 11.02
Capital Expenditure -6.7 -.3 -.1 -.1 .0 -.8 -.7 -.6 -.6 -.5
Capital Expenditure, % -1.99 -0.10735 -0.02762457 -0.03896077 0 -0.4321 -0.4321 -0.4321 -0.4321 -0.4321
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -277.5 -341.8 -226.9 -89.9 -44.5 -112.7 -102.5 -93.3 -84.9 -77.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -363.7 -239.1 -200.5 -43.4 -2.4 -88.0 -76.9 -70.0 -63.7 -57.9
WACC, % 7.41 7.33 7.27 7.44 7.44 7.38 7.38 7.38 7.38 7.38
PV UFCF
SUM PV UFCF -293.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -59
Terminal Value -1,098
Present Terminal Value -769
Enterprise Value -1,063
Net Debt 61
Equity Value -1,124
Diluted Shares Outstanding, MM 187
Equity Value Per Share -6.00

What You Will Get

  • Real AKBA Financial Data: Pre-filled with Akebia Therapeutics’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Akebia Therapeutics’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive Data: Akebia Therapeutics’ historical financial reports and projected forecasts.
  • Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Calculations: Observe Akebia’s intrinsic value update instantly.
  • Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A reliable resource for analysts, investors, and finance professionals.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Akebia Therapeutics, Inc.'s pre-filled financial data and forecasts.
  3. Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
  5. Step 5: Evaluate the outputs and leverage the results for investment decisions.

Why Choose Akebia Therapeutics, Inc. (AKBA)?

  • Innovative Solutions: Pioneering therapies that address unmet medical needs in kidney disease.
  • Proven Expertise: A team of industry leaders dedicated to advancing renal health.
  • Commitment to Research: Continuous investment in clinical trials and scientific exploration.
  • Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
  • Strong Partnerships: Collaborations with top research institutions and healthcare providers.

Who Should Use This Product?

  • Investors: Accurately assess Akebia Therapeutics' fair value before making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Akebia Therapeutics (AKBA).
  • Consultants: Effortlessly modify the template for valuation reports tailored to clients interested in Akebia Therapeutics (AKBA).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotechnology sector.

What the Template Contains

  • Preloaded AKBA Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.